ARTICLE | Emerging Company Profile
Epigenetics: It’s personal
Stelvio brings personalized medicine to GBM stem cells
July 12, 2017 4:59 PM UTC
Stelvio Oncology is using the wide inter- and intra-tumoral diversity of glioblastoma multiforme (GBM) tumors to create a personalized medicine platform that drives GBM stem cells to adopt benign cell fates based on patient-specific epigenetic signatures.
According to co-founder and CEO Attila Hajdu, the company can convert cancer cells to healthy cells by taking advantage of epigenetic signatures that are unique to particular cell types or states...
BCIQ Target Profiles